Related Experiment Video

Updated: Nov 7, 2025

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.2K

Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer

Naheed Arfin Borah1,2, Mamatha M Reddy1,2

  • 1The Operation Eyesight Universal Institute for Eye Cancer, L.V. Prasad Eye Institute, Bhubaneswar 751024, India.

Molecules (Basel, Switzerland)
|April 30, 2021
PubMed

Insights

Aurora kinase B (AURKB) is crucial in cell division and cancer. Inhibiting AURKB shows promise as a cancer therapy, with several small molecule inhibitors in development for various tumors.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Aurora kinase B (AURKB) is a key mitotic kinase involved in cell cycle regulation.
  • AURKB deregulation and overexpression are linked to tumor progression, invasion, metastasis, and drug resistance.

Purpose of the Study:

  • To review the role of AURKB in cancer development and therapy resistance.
  • To summarize the therapeutic potential of AURKB inhibition and discuss ongoing drug development.

Main Methods:

  • Literature review of recent findings on AURKB.
  • Analysis of preclinical and clinical studies of AURKB inhibitors.
  • Examination of combination therapy strategies involving AURKB inhibition.

Main Results:

  • AURKB plays a significant role in tumor growth and resistance to cancer therapies.
  • Numerous small molecule inhibitors targeting AURKB are under investigation.
  • Combination therapies involving AURKB inhibitors show potential for enhanced efficacy.

Conclusions:

  • AURKB is a validated drug target for cancer therapy.
  • Targeting AURKB offers a promising strategy to overcome tumor progression and drug resistance.
  • Further research into AURKB inhibitors and combination therapies is warranted.
Keywords:
AURKB inhibitorsAURKB regulationaurora kinase B (AURKB)cancercombination therapytherapy related drug resistance

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K